{
    "ticker": "ODTC",
    "name": "Odyssey Therapeutics, Inc.",
    "description": "Odyssey Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapies for cancer and autoimmune diseases. Founded in 2020, Odyssey leverages its proprietary platform to identify and validate novel targets that can lead to breakthrough treatments. The company\u2019s mission is to transform the treatment landscape for patients suffering from serious diseases by harnessing the power of advanced drug discovery technologies. With a robust pipeline of drug candidates, Odyssey is committed to addressing unmet medical needs through strategic collaborations and partnerships with academic institutions and industry leaders. The company's research is driven by a deep understanding of disease biology and a commitment to scientific excellence, aiming to bring transformative therapies from the laboratory to patients efficiently. Odyssey's team is composed of experts in the fields of biochemistry, pharmacology, and clinical development, united by a shared vision of improving patient outcomes through innovative medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2020",
    "website": "https://www.odysseytx.com",
    "ceo": "Dr. Mark A. Goldsmith",
    "social_media": {
        "twitter": "https://twitter.com/OdysseyTx",
        "linkedin": "https://www.linkedin.com/company/odyssey-therapeutics/"
    },
    "investor_relations": "https://ir.odysseytx.com",
    "key_executives": [
        {
            "name": "Dr. Mark A. Goldsmith",
            "position": "CEO"
        },
        {
            "name": "Dr. Julie A. H. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "OTX-101",
                "OTX-201"
            ]
        },
        {
            "category": "Autoimmune Diseases",
            "products": [
                "OTX-301"
            ]
        }
    ],
    "seo": {
        "meta_title": "Odyssey Therapeutics, Inc. | Innovative Cancer and Autoimmune Therapies",
        "meta_description": "Explore Odyssey Therapeutics, Inc., a biopharmaceutical company dedicated to developing groundbreaking therapies for cancer and autoimmune diseases. Discover their innovative research and commitment to patient care.",
        "keywords": [
            "Odyssey Therapeutics",
            "Biotechnology",
            "Pharmaceuticals",
            "Cancer Treatment",
            "Autoimmune Diseases",
            "Drug Discovery"
        ]
    },
    "faq": [
        {
            "question": "What is Odyssey Therapeutics focused on?",
            "answer": "Odyssey Therapeutics is focused on discovering and developing innovative therapies for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Odyssey Therapeutics?",
            "answer": "Dr. Mark A. Goldsmith is the CEO of Odyssey Therapeutics, Inc."
        },
        {
            "question": "Where is Odyssey Therapeutics headquartered?",
            "answer": "Odyssey Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are the main product categories of Odyssey Therapeutics?",
            "answer": "Odyssey's main product categories include oncology and autoimmune diseases."
        },
        {
            "question": "When was Odyssey Therapeutics founded?",
            "answer": "Odyssey Therapeutics was founded in 2020."
        }
    ],
    "competitors": [
        "MRNA",
        "BMRN",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}